HCC

In an interview with Targeted Oncology, Laura Dawson, MD, FRCPC, discussed the results of the phase 3 NRG/RTOG 1112 study of SBRT followed by sorafenib compared with sorafenib alone in locally advanced hepatocellular carcinoma.

The first-in-class PPT-1 inhibitor ezurpimtrostat has been granted an orphan drug designation by the FDA for patients with hepatocellular carcinoma.

The phase 3 NRG/RTOG 1112 adds to the body of evidence for the role of external beam radiation, bringing SBRT to the armamentarium of treatment for patients with locally advanced hepatocelluar carcinoma, according to Laura Dawson, MD, FRCPC.

Patients with hepatocellular carcinoma treated from 2018 to 2021 experienced better efficacy vs patients treated from 2008 to 2018, according to a real-world study.

Results from the phase 2 Talem trial, presented at the 2023 Gastrointestinal Cancers Symposium, showed the promising signs of efficacy, anti-tumor activity, and tolerable adverse events when combining blank-microsphere transarterial chemoembolization with lenvatinib and sequential microwave ablation for patients with HCC.

Favorable safety and efficacy data were seen with envafolimab, lenvatinib and transarterial chemoembolization in patients with unresectable hepatocellular carcinoma.

Anti-drug antibodies did not seem to affect how well the STRIDE regimen of durvalumab and tremelimumab or durvalumab alone worked in patients with unresectable hepatocellular carcinoma.

Data from the health-related quality of life analysis of the LEAP-002 study showed similar scores with the addition of pembrolizumab to lenvatinib vs placebo plus lenvatinib in patients with hepatocellular carcinoma.

Laura A. Dawson, MD, FRCPC, discusses findings from the NRG/RTOG 1112 study of stereotactic body radiation therapy followed by sorafenib vs sorafenib alone in hepatocellular carcinoma.

Better health-related quality of life outcomes were seen with tislelizumab vs sorafenib in patients with hepatocelluar carcinoma.

Patients with advanced hepatocellular carcinoma who were treated with lenvatinib following progression on immunotherapy had a median overall survival of 12.8 months and progression-free survival of 3.7 months.

In IMbrave050, the risk of disease recurrence or death was decreased with adjuvant atezolizumab and bevacizumab compared with active surveillance in patients with early-stage hepatocellular carcinoma.

Milind Javle, MD, discusses the phase 3 HIMALAYA study of durvalumab and tremelimumab in patients with locally advanced or metastatic hepatocellular cancer.

During a Targeted Oncology case-based roundtable event, Amit Singal, MD, discussed the data from the LEAP-002 trial of lenvatinib/pembrolizumab vs lenvatinib in patients with hepatocellular carcinoma.

Ghassan K. Abou-Alfa, MD, discusses the data from a phase 3 trial evaluating camrelizumab and rivoceranib vs sorafenib in the first-line for unresectable hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Richard S. Finn, MD, discussed the case of a patient with a 4.5-cm Liver Imaging Reporting and Data System category 5 (LR-5) hepatic mass, Crohn disease, and cirrhosis.

Richard Kim, MD, walks through options in the frontline setting for patients with advanced staged hepatocellular carcinoma and how newer treatments have impacted this patient population.

Milind Javle, MD, discusses the use of durvalumab for locally advanced or metastatic biliary tract cancer.

Ghassan K. Abou-Alfa, MD, discusses the LEAP-002 study of pembrolizumab plus lenvatinib vs lenvatinib alone in patients with unresectable hepatocellular carcinoma.

In data from a first-in-human study of a novel MPS1 inhibitor in patients with advanced solid tumors, clinical activity was observed.

Richard S. Finn, MD, discusses key takeaways of the LEAP-002 trial of frontline pembrolizumab and lenvatinib for hepatocellular carcinoma.

During a Targeted Oncology case-based roundtable event, Ghassan K. Abou-Alfa, MD, MBA, discusses with participants the unexpected results of the LEAP-002 trial of lenvatinib plus pembrolizumab versus pembrolizumab alone for patients with hepatocellular carcinoma. This is the second of 2 articles based on this event.

OTX-2002 has received an orphan drug designation by the FDA for patients with hepatocellular carcinoma. The agent will further be evaluated in the phase 1/2 MYCHELANGELO trial.

Pierre Gholam, MD, discusses standard of care options for hepatocellular carcinoma, including newly-available therapies.

Considering the higher-than-average rate of liver cancer in Texas as a whole, it was unexpected that the Kashmere Gardens neighborhood cluster would be linked to environmental issues. Texas Department of State Health Services and the City of Houston confirm the cluster exists and is caused by toxins polluted into the soil by The Union Pacific Railroad.

Richard S. Finn, MD, discusses the background on lenvatinib and what led to the development of the LEAP-002 trial.

During a live virtual event, Ghassan K. Abou-Alfa, MD, discussed the results of the REFLECT trial of lenvatinib versus sorafenib and the LEAP-002 trial of lenvatinib/pembrolizumab versus lenvatinib in patients with hepatocellular carcinoma.

Mahvish Muzaffar, MD, and Nasreen Vohra, MD, from the Brody School of Medicine/East Carolina University, discuss the past decade of progress in treatment for patients with hepatocellular carcinoma.

Findings from the phase 3 HIMALAYA trial have led the FDA to grant approval to the combination of tremelimumab and durvalumab for the treatment of patients with unresectable hepatocellular carcinoma.

TTI-101, an oral, small molecule, STAT3 inhibitor, has been granted fast track designation by the FDA for patients with hepatocellular carcinoma.